Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine
NCT ID: NCT01548326
Last Updated: 2012-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
52 participants
INTERVENTIONAL
2011-09-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
NCT00452842
The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23
NCT02097589
Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine
NCT05551624
COVID-19 Vaccination Detoxification in LDL-C
NCT05839236
Atorvastatin Study in Cardiovascular Disease Risk
NCT02392416
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin
will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
Atorvastatin
one 40 mg Atorvastatin tablet orally per day for 10 days
Placebo
will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
placebo
one Placebo tablet orally per day for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
one 40 mg Atorvastatin tablet orally per day for 10 days
placebo
one Placebo tablet orally per day for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Negative HBc Ab
* Negative HBs Ag
* HBs Ab less than 10 in ELIZA
Exclusion Criteria
* Chronic use of Atorvastatin
* Immunosuppressive Disease
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nematollah Jonaidi Jafari
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nematollah Jonaidi Jafari
Head of Health Research Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nematollah Jonaidi Jafari, MD
Role: STUDY_CHAIR
Baqiyatallah University of Medical Sciencesc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baqiyatallah University of Medical Sciences
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRCT201109147556N1
Identifier Type: REGISTRY
Identifier Source: secondary_id
behdasht-90-6-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.